(2023). A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant is Not Planned as Initial Therapy. WHO International Clinical Trials Registry Platform.
Chicago Zitierstil"A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed By Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant Is Not Planned As Initial Therapy." WHO International Clinical Trials Registry Platform 2023.
MLA Zitierstil"A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed By Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant Is Not Planned As Initial Therapy." WHO International Clinical Trials Registry Platform 2023.